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Abstract. Na+/H+ exchanger regulatory factor 1 (NHERF1)
has been reported to interact with post-synaptic density
protein/Drosophila disc large tumour suppressor/zonula
occludens 1 protein (PDZ) binding proteins by its two PDZ
domains. These associations have effects on cellular signal
transductions. NHERF1 has also been indicated as a cancer-
related gene in several solid tumour types. We identified a novel
mutation (A190D), of the PDZ2 domain of NHERF1 in breast
cancer tissues. NHERF1 A190D mutation abolished NHERF1
modulation of proliferation and migration. In this study, we
found that NHERF1 A190D mutation increased nuclear
localisation of the protein compared to wild-type NHERF1. It
has been reported that YES-associated protein (YAP) interacts
with NHERF1. Here we found that NHERF1 A190D mutation
increased the binding affinity between NHERF1 and YAP, which
inhibited the phosphorylation of YAP. These data suggest that
wild-type NHERF1 acts as a tumour suppressor, while NHERF1
A190D mutation abolishes the tumour-suppressive effect in
cancer cells, due to A190D mutation-mediated nuclear
NHERF1 translocation and induction of YAP phosphorylation. 
Na+/H+ exchanger regulatory factor 1 (NHERF1) is a typical
scaffold protein of the post-synaptic density protein/ Drosophila
disc large tumour suppressor/zonula occludens 1 protein (PDZ)
domain-containing protein family. NHERF1 has two PDZ
domains, PDZ1 and PDZ2, followed by an ezrin–radixin–
moesin binding region (1). The PDZ1 domain (11-97 amino
acids) of NHERF1 binds to proteins containing the PDZ
binding motif such as epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor (PDGFR), phosphatase
and tensin homolog deleted on chromosome 10 (PTEN), beta
2-adrenergic receptors, cystic fibrosis transmembrane
conductance regulator and spleen tyrosine kinase (SYK) (2-7),
while the PDZ2 domain (150-237 amino acids) of NHERF1
binds to other proteins such as yes-associated protein 65
(YAP65), sodium hydrogen exchanger 3, phospholipase C β3
and β-catenin (8-13). These protein interactions lead to changes
in subcellular location of the proteins and cellular functions by
different signal pathways (14, 15). 
Genetic alterations of cancer-related genes, such as p53,
PTEN, breast cancer 1 (BRCA1) and BRCA2, have been
reported to affect carcinogenesis and progression (16-19).
NHERF1 has been shown to be a potential cancer-related gene
and suppressor of tumour growth (20-22). Genetic mutations of
NHERF1 have also been reported in some cancer tissues and
cancer cell lines. Several missense mutations have been found
in the two PDZ domains of NHERF1 which have impacts on
cellular functions. For example, NHERF1 E43G mutation has
been found to inhibit EGFR signaling (23). NHERF1 E68A
mutation has been found to abolish the association with type 2a
sodium-phosphate co-transporter to affect cyclic AMP (cAMP)
production and protein kinase C activity (15). Missense
mutation NHERF1 R153Q, K172N and R180W in exon 2 have
been found in primary breast tumours and MDA-MB-231 cell
lines and are related to protein stability or alter the interaction
between NHERF1 and SYK/PTEN/PDGFR (7, 24, 25).
Missense mutation NHERF1 E225K in exon 3 expressed in
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cultured renal cells which also related to protein stability, the
generation of cAMP and phosphate transportation (26).
In the present study, we identified a novel mutation of
NHERF1, A190D, and explored its effects on cellular
functions and interactions with signal molecules. The results
indicate that this new NHERF1 mutation has important
implication on the biological functions of cancer cells, in
carcinogenesis and progression.
Materials and Methods
Cell lines and culture. Human breast cancer cell line MCF-7 and non-
small cell lung cancer cell line SK-MES-1 were obtained from the
European Collection for Animal Cell Cultures (Salisbury, Wiltshire,
UK). MCF-7-riNHERF1 cell lines were constructed by stable
transfection of MCF-7 cells with ribozyme targeted to NHERF1
thereby knocking down expression of NHREF1 (25). HEK-293 and
COS-7 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). All cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
foetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin
(Gibco BRC, Paisley, UK) at 37˚C, with 5% CO2. 
Human mammary specimens. Tissue samples were obtained from a
total of 20 Chinese patients who had breast cancer. The tissues were
collected immediately after mastectomy and snap-frozen in liquid
nitrogen. The study received local Ethics Research Committee
(approval number 2013SY15). None of the patients had any
underlying medical condition and none was taking any medication.
The genomic DNA from 20 frozen Chinese breast cancer tissues was
extracted using the DNeasy kit (Qiagen, Hilden, Germany). All six
exons of NHERF1 were amplified by PCR as described before (23).
The amplified sequences were analysed by single-strand conformation
polymorphism also as previously described (27). 
Plasmids and cell transfection. The cDNA of wild-type NHERF1
(NHERF-WT) and NHERF1 A190D mutation were obtained by
polymerase chain reaction (PCR) and cloned into pEASY™-M2 vector
using pEASY-Blunt M2 Expression Kit (TransGen, Beijing, China)
according to the manufacturer’s instructions. Green fluorescent protein
(GFP)-NHERF-WT and GFP-NHERF-A190D constructs were verified
by DNA sequencing. Glutathione-S-transferase (GST)-NHERF1
construct was kindly provided by Dr. Jiale Dai (MD Anderson Cancer
Center, Houston, TX, USA). GST-NHERF-A190D mutation construct
was generated from the wild type using Fast MultiSite Mutagenesis
System kit (TransGen) and verified by DNA sequencing.
Cell transfections were performed using Lipofectamine reagent
(Invitrogen, Carlsbad, CA, USA) by following the manufacturer’s
instructions. The stably transfected cell lines were selected in selected
culture medium containing 600 μg/ml G418. The expression of
NHERF1 was verified by western blotting.
Cell proliferation assay. MCF-7-riNHERF1 and SK-MES-1 cells
were seeded into 96-well plates in sextuplicate at a density of 2,000
cells per well. Plates were then incubated for 24, 48, 72 and 96 h
before added CCK-8 reagent (Dojindo, Kumamoto, Japan), by
following the manufacturer’s instructions. The absorbance was
measured at 450 nm using EnSpire label microplate reader
(PerkinElmer, Waltham, MA, USA). 
Wound-healing assay. MCF-7-riNHERF1 and SK-MES-1 cells were
seeded into 6-well plates at a density of 5×105 cells per well and
cultured until confluent. The layer of cells was scraped with a 5-
gauge needle to create a wound. Images of the wound were recorded
under microscopy at different time points (0, 6, 12 and 24 h). The
width of wounds was evaluated by Image-Pro plus (National
Institutes of Health, Bethesda, MD, USA).
Immunofluorescence staining. HEK-293 cells were seeded on a
cover glass in 6-well plates and cultured overnight. The adherent
cells were fixed with 4% paraformaldehyde and stained with 5
μg/ml Hochest 33258 (Zhongshan, China). Images were acquired
under confocal microscopy (LAS AF-TCS SP5; Leica Microsystems
Inc., Exton, PA, USA).
Nuclear and cytoplasmic protein extraction. The nuclear and
cytoplasmic protein extracts were prepared using the Nucl-Cyto-
Mem Preparation kit (Applygen Technologies, China) according to
the manufacturer’s instructions. Briefly, the HEK-293 cells were
digested and washed with cold phosphate-buffered saline. Then the
cell pellets from centrifugation were incubated with cytoplasmic
extraction and nuclear extraction reagent. The extractis were
analysed by western blotting.
GST pull-down assays and western blotting. GST pull-down assays
and western blotting were performed as described previously (28).
Antibody to NHERF1 was purchased from Becton Dickinson
Company (Franklin Lake, NJ, USA), Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). GFP was purchased
from MBL life science (Nagoya, Japan). Histone deacetylase protein
(HDAC) (Santa Cruz Biotechnology) was used as nuclear protein
control, and α-tubulin was used as cytoplasmic protein control
(Santa Cruz Biotechnology). YAP was purchased from Santa Cruz
Biotechnology (Santa Cruz Biotechnology) and phospho-YAP
(Ser127) was purchased from Cell Signalling Technology (Beverly,
MA, USA). Horseradish peroxidase-conjugated secondary
antibodies were obtained from ZSGB-BIO (Beijing, China).
Statistical analysis. Statistical analysis was performed using SPSS
(IBM Corp, Armonk, New York, US). p-Value of less than 0.05 was
considered to be statistically significant. 
Results
NHERF1 A190D mutation identified in breast cancer. A
novel point-mutation, cytosine mutated to adenine at
nucleotide position 569, was confirmed by DNA sequencing
(Figure 1A). This point-mutation resulted in substitution in
codon 190 (Ala/A-Asp/D), and is named here as A190D.
The alanine 190 has been highly conserved in the PDZ2
domain of NHERF1 protein throughout evolution with other
species as shown by the alignment of the NHERF1 protein
sequence (Figure 1B). This suggests that the novel A190D
mutation, not found in the 1000 Genomes Project database
(http://browser.1000genomes.org/index.html), has the
potential to affected the scaffold functions of the NHERF1
protein.
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NHERF1 A190D mutation abolished the NHERF1 inhibition
of cellular proliferation and migration. SK-MES-1 and MCF-
7-riNHERF1 breast cancer cells were used in proliferation and
migration assays because NHERF1 was poorly expressed in
SK-MES-1 cells (23). Our previous studies showed NHERF1
as a tumour-suppressor gene in breast cancer cells (25). SK-
MES-1 cells were stably transfected with NHERF1 WT or
A190D mutation plasmid and expressions was detected by
western blotting (Figure 2A). The expression of WT and
mutated NHERF1 protein in the respectively transfected cells
was considerably increased compared to parental and vector
control cells. The impact of NHERF1 A190D mutation on
cellular proliferation and migration were subsequently tested
with these cells. The rate of cell proliferation induced by
NHERF1 A190D mutation increased by 35% (day 3)
compared to WT NHERF1 (Figure 2B). Cellular migration in
the wound-healing assay by cells carrying NHERF1 A190D
mutation increased by 121% (12 h) compared to cells with
WT NHERF1 (Figure 2C). 
MCF-7 cells expressed high levels of NHERF1. Using
riNHERF1 plasmids, we established a stable NHERF1
knockdown cell line, MCF-7-riNHERF1, following
transfection and selection. NHERF1-WT or NHERF1 A190D
mutation plasmids were then stably transfected into the MCF-
7-riNHERF1 cells, which resulted in expression of both WT
and mutated NHERF1 proteins, respectively, as detected by
western blotting (Figure 2A). Using these new MCF7 sublines,
it was found that cellular proliferation and migration increased
59% (day 3) and 120% (12 h), respectively induced by
NHERF1 A190D mutation compared to WT NHERF1 (Figure
2B and C). These results indicate that NHERF1 A190D
mutation abrogated the inhibition of proliferation and migration
by NHERF1 in SK-MES-1 and MCF-7-riNHERF1 cells. 
Subcellular localization of mutated NHERF1 protein. As
reported before (29), mutation of NHERF1 affects subcellular
localization of its protein. We therefore also explored the
effect of NHERF1 A190D mutation on localization by
confocal assay. NHERF1-WT and NHERF-A190D were
transfected into HEK-293 cells separately and detected by
confocal microscopy. The fluorescence intensity in the nucleus
increased, indicating a rise in nucleus localization of mutated
NHERF1 protein, in clear contrast to the WT NHERF1 protein
(Figure 3A). To further confirm this finding, the cytoplasmic
and nuclear fractions were extracted from the respective cells
and the levels of proteins in these fractions were further
analysed by western blotting. Mutated NHERF1 protein was
increased in the nucleus but decreased in the cytoplasm
compared with WT NHERF1 protein using HDAC and α-
tubulin as nuclear and cytoplasmic protein controls,
respectively, in clear contrast to cells transfected with
NHERF1-WT (Figure 3B and C). These data indicate
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Figure 1. A: Novel mutation of Na+/H+ exchanger regulatory factor (NHERF1) (A190D) identified in patients with breast cancer. A: The NHERF1
gene mutation (GCT to GAT) was identified by sequencing, which would cause a switch of codon 190 (Ala/A-Asp/D). B: The mutation site
corresponded to a conserved basic residue in the post-synaptic density protein/Drosophila disc large tumour suppressor/zonula occludens 1 protein
(PDZ)2 domain of NHERF1 protein. 
NHERF1 A190D mutation results in increased translocation
of NHERF1 protein to the nucleus compared to WT NHREF1.
NHERF1 A190D mutation enhances NHERF1 association
with YAP. It has been reported NHERF1 associates with YAP
through its PDZ2 domain (8). To determine the impact of
NHERF1 A190D mutation on the interaction between
NHERF1 and YAP, GST pull down assay was carried out.
GST-NHERF1-WT and GST-NHERF1-A190D fusion proteins
were purified and incubated with lysates of COS-7 cell
expressing full-length YAP. It was very interesting to note that
the level of YAP associated with mutated NHERF1 fusion
protein increased by 59% compared with WT NHERF1
(Figure 4A and B). The results indicate that YAP preferentially
associated with mutated NHERF1 protein.
NHERF1 A190D mutation affects phosphorylation of YAP.
Phosphorylation of YAP is essential for its translocation into
the nucleus in order for it to act as transcriptional co-
activator. Therefore, we investigated the effect of mutated
NHERF1 on interaction and phosphorylation of YAP.
Overexpression of NHERF1 facilitated the phosphorylation
of YAP. Phosphorylation of YAP was seen in both both
NHERF1-A190D and NHERF1-WT transfected cells.
ANTICANCER RESEARCH 37: 67-74 (2017)
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Figure 2. A: Na+/H+ exchanger regulatory factor (NHERF1)-wild type (WT) and the NHERF1-A190D plasmids were stably transfected into SK-
MES-1 cells and MCF-7 cells in which NHERF1 was stably knocked-down by riNHERF1 (MCF-7-riNHERF1). NHREF1 protein expression was
then detected by western blotting. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading controls. NHERF1 A190D mutation
abolished the inhibition of proliferation (B) and migration (C) induced by WT NHERF1 in SK-MES-1 cells and MCF-7-riNHERF1 cells. The results
represent mean values±SD of three independent experiments. *p<0.05. 
However, the phosphorylation of YAP in cells carrying
NHERF1 A190D was significantly lower than that in cells
with WT NHERF1 (Figure 5).
Discussion 
The NHERF1 gene has been reported as a cancer-related gene
in breast cancer. Up-regulation of NHERF1 in tumours has
been associated with carcinogenesis, progression, and poor
prognosis, indicating that NHERF1 is a potential oncoprotein
in breast cancer and colon cancer (30, 31). However in
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Figure 3. A: Na+/H+ exchanger regulatory factor 1 (NHERF1) A190D
mutation increased the localization of NHERF1 protein in the nucleus
of HEK-293 cells compared to wild-type (WT) NHERF1, as analyzed by
confocal microscopy. B: Expression of NHERF1 A190D mutation
increased in nucleus and decreased in the cytoplasm of HEK-293 cells
compared with WT NHERF1 as shown by western blotting. C:
Quantification of the expression of NHERF1 shown in (B). Histone
deacetylase protein (HDAC) and α-tubulin were used as nucleus and
cytoplasm loading controls. The results represent mean values±SD of
three independent experiments. *p<0.05. 
Figure 4. Na+/H+ exchanger regulatory factor (NHERF1) A190D
mutation enhanced the association between NHERF1 and YES-
associated protein (YAP). A: Glutathione-S-transferase (GST) fusion
with NHERF1 WT or A190D proteins were purified and incubated with
COS-7 cells. The pulled-down precipitation was assayed by western
blotting. B: Quantification of YAP pulled down by GST-NHERF-WT and
GST-NHERF-A190D fusion proteins. The results represent mean
values±SD of three independent experiments. *p<0.05. 
Figure 5. Na+/H+ exchanger regulatory factor (NHERF1) A190D
mutation increased phosphorylation of YES-associated protein (YAP) in
MCF-7 cells in which NHERF1 was stably knocked-down by riNHERF1
(MCF-7-riNHERF1). A: NHERF1-WT or -A190D mutation fusion
plasmid was transfected separately into MCF-7-riNHERF1 cells. YAP
and phosphorylated YAP (P-YAP) were detected by western blotting. B:
Quantification of P-YAP shown in (A). The results represent mean
values±SD of three independent experiments. *p<0.05. 
contrast, NHERF1 has been to shown to act as anticancer gene
in invasive breast carcinomas and breast cancer cells (21, 32).
These contrasting results may suggest that NHERF1 has
diverse roles in breast cancer, possibly via different patterns
of expression or mutations in different subtypes.
In our previous study, we found NHERF1 to act as an
anticancer gene related to malignant phenotypes (25). There
have been several reports of missense mutations in NHERF1
PDZ domains in human breast cancer (7, 23, 25, 29). In the
present study, the coding region and the intron-exon junctions
of NHERF1 were analysed in 20 human breast cancer tissues.
A novel NHERF1 sequence variant (GCT to GAT), resulted in
an amino acid change at residue 190 from alanine to aspartic
acid, in the PDZ2 domain of NHERF1. We found
overexpression of mutated NHERF1 abolished the suppression
of proliferation and migration induced with WT NHERF1 in
NHERF1 knock-down cells. This suggests WT NHERF1 has
a tumour-suppressive role, while NHERF1 A190D mutation
abolishes this tumour suppressive function of NHERF1
protein. 
NHERF1 A190D mutation changed nonpolar alanine to
acidic polar aspartic acid. This might lead to spatial structural
changes of NHERF1 protein, resulting in alteration of
subcellular location and biological activities in cancer cells.
NHERF1 is a typical scaffold protein and plays a role in
cellular trafficking of other proteins (33). It has been well-
established that the trafficking proteins of different sub-
localization may have different functions in the cells (34,
35). In this study, we found NHERF1 A190D mutation
resulted in an increase in the nuclear level of NHERF1, in a
clear contrast to the WT NHERF1 protein. It has been shown
that the PDZ1 domain of the NHERF1 protein is important
in the importing the NHERF1 protein into the nucleus (29).
The reported mutation in the present study is located at the
PDZ2 domain of NHERF1. Our findings also show the
PDZ2 domain of NHERF1 has an influence in importing this
to the nucleus. 
YAP (also known as YAP1 or YAP65) can interact with
NHERF1 (8). YAP was first identified by its ability to
associate with the SH3 domain of YES and SRC protein
tyrosine kinases. When YAP is located in the nucleus, it acts
as a transcriptional co-activator in cellular proliferation and
other cancer-related malignant pathway (36). In this study, we
found NHERF1 A190D mutation also appears to affect YAP
function. The phosphorylation of YAP at serine 127 residue
promotes its binding to 14-3-3 and impairs the nuclear import
of YAP (37-39). NHERF1 A190D mutation led to a decrease
in YAP phosphorylation. An increased binding affinity
between mutated NHERF1 and YAP would lead to less
phosphorylation of YAP, as shown in the present study.
Therefore, the association between 14-3-3 protein and the
phosphorylated serine residue of YAP would also decrease,
facilitating YAP translocation into the nucleus and increasing
its transcriptional activity. The novel influence of NHERF1
point mutation on cellular proliferation and migration suggests
the regulation of PDZ scaffold protein would have great
impact on cancer cells. 
Here we found a novel NHERF1 A190D mutation which
rescued cells from inhibited proliferation and migration by
WT NHERF1, and affected localisation of NHERF1 and YAP
proteins, both of which may have profound effects on cancer
cell behaviour.
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